SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : LIPO-Liposome
LIPO 0.3090.0%Dec 11 10:33 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cheeseburger who wrote (781)8/30/1999 3:35:00 PM
From: G-MAN  Read Replies (2) of 900
 
I am wondering if the market is pushing this stock back to a price that would fairly represent the value of this company with the approval of Evacet.

I read a H&Q report issued back in July and they mentioned that the current price of $18 (& some change) represented the fair value of LIPO with the Evacet approval. Without Evacet, they mentioned that $12 was a fair value.

They also mentioned that they reviewed the data provided by the company and see a strong case for recommendation. It is interesting that they see a positive light and this Avalon Group, that has been shorting the stock, sees it the other way.

Given this estimate, I am now wondering if we will see LIPO pull back to $16 to 18. With a positive recommendation, we might see the mid 20's for a brief moment. The price action of this stock is not acting as if:

A)a positive recommendation will be received, or
B)it is fairly valued as of this moment in time.

My guess is that the stock price is a little overpriced. For those of us who bought into the stock in the 20's expecting a price of $30 soon, we might be disappointed for the time being. For those who bought in the low teens, I see relatively low risk.

Are there any thoughts?

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext